AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04268511 — intervention group
Intervention type: PROCEDURE
Intervention: Caudal epidural block group
Description: The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
Study NCT04268511 — intervention group
Intervention type: PROCEDURE
Intervention: Pudendal nerve block group
Description: A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
Study NCT00849472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin + cyclophosphamide
Description: 4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
Study NCT00849472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + pazopanib
Description: 4 cycles of paclitaxel + pazopanib
Study NCT00849472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: neoadjuvant surgery for breast cancer
Study NCT00849472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib monotherapy
Description: 6 months of treatment with pazopanib monotherapy
Study NCT00834938 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03193268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-blind RTC of PD patients
Description: The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
Study NCT03193268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling
Description: Patients must undergo a daily exercise cycle of 1 hour during the intervention
Study NCT02068599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Study NCT02068599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Study NCT04041128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lynparza
Description: Lynparza taken orally at a dose of 300mg twice daily for 7 days
Study NCT01428128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
Study NCT04076215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stressogenic stimulus
Description: Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
Study NCT04076215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobeat smart watch and adhesive biosensor patches.
Description: Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
Study NCT00680173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study NCT02439619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TechCare
Description: The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
Study NCT02478502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
Study NCT01470807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable artificial pancreas system with CTR algorithms
Description: The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
Study NCT01209468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monobloc oral appliance
Description: one piece oral appliance
Study NCT01209468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: twinblock oral appliance
Description: two-piece oral appliance
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bamlanivimab 7000mg
Description: Administered by single IV infusion. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-196+BRII-198
Description: 1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442 (IV)
Description: 300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442 (IM)
Description: Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNG001
Description: 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986414 + BMS-986413
Description: Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185 (3,840 Units/kg)
Description: Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185 (10,240 Units/kg)
Description: Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CASIRIVIMAB + IMDEVIMAB
Description: 600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Bamlanivimab 7000mg
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Bamlanivimab 700mg
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BRII-196+BRII-198
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study NCT02913625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided retroclavicular block
Description: Ultrasound guided retroclavicular block for forearm or hand surgery
Study NCT02913625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided infraclavicular block
Description: Ultrasound guided infraclavicular block for forearm or hand surgery
Study NCT05343910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma massage
Description: The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
Study NCT04459962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath Test & Cheek Swab
Description: Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
Study NCT00336362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis.
Study NCT01104831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: cooled sleeve placed over fracture site.
Study NCT01104831 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Room temperature cuff
Description: sleeve with room temperature water placed over fracture site.
Study NCT02500550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATIR101
Description: T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
Study NCT02500550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation (HSCT)
Description: CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)
Study NCT02500550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TBI regime
Description: * Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.
Study NCT02500550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-TBI regime
Description: * Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.
Study NCT03371719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT03371719 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT03371719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT03371719 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02333708 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Study NCT01047410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
Study NCT01047410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention and dietary advice
Description: The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
Study NCT04038333 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any interventions.
Study NCT02605577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new systemic nutrition management protocol
Description: a new established systemic nutrition management protocol
Study NCT02721862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
Study NCT00834249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study NCT03853005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVHDF
Description: Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
Study NCT03853005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: controlled
Description: Patients will receive the usual care
Study NCT00041392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 100 mg/kg
Study NCT00041392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Placebo
Study NCT02069080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64-Cu-plerixafor
Description: Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion.
Study NCT02005497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthLinks
Study NCT02005497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HealthLinks
Study NCT01250080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition with Glutamine
Description: daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
Study NCT01250080 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Total Parenteral Nutrition without glutamine
Description: The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
Study NCT03848507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin 20%
Description: Intravenous administration of 20% albumin during cystectomy
Study NCT02622386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
Study NCT02622386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule taken daily for 12 weeks.
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form: solution Route of administration: subcutaneous injection
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statins
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholestyramine
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02890992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02721862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
Study NCT02721862 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Gallbladder Ultrasound
Description: Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
Study NCT02721862 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallbladder Ultrasound
Description: Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
Study NCT01645163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling using mobile phones
Description: Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
Study NCT05076968 — intervention group
Intervention type: PROCEDURE
Intervention: Complete denture fabrication
Description: Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
Study NCT02354950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
Study NCT04518410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SNG001
Description: Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.